Editas Medicine (EDIT) News Today → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free EDIT Stock Alerts $5.56 +0.53 (+10.54%) (As of 04:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 9 at 4:53 PMEditas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPSmarketbeat.com - May 9 at 1:45 PM1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?fool.com - May 9 at 1:12 PMEditas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Ratingmarkets.businessinsider.com - May 9 at 11:52 AMBuy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth Outlookmarkets.businessinsider.com - May 9 at 11:52 AMEditas Medicine (NASDAQ:EDIT) Given New $9.00 Price Target at Barclaysmarketbeat.com - May 9 at 11:46 AMEditas Medicine (NASDAQ:EDIT) Lifted to Equal Weight at Morgan Stanleymarketbeat.com - May 9 at 7:07 AMEditas Medicine First Quarter 2024 Earnings: Misses Expectationsfinance.yahoo.com - May 9 at 6:52 AMEditas: Q1 Earnings Snapshotwashingtonpost.com - May 8 at 8:49 PMEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024investorplace.com - May 8 at 1:15 PMEditas Medicine Announces First Quarter 2024 Results and Business Updatesglobenewswire.com - May 8 at 7:00 AMGene Editing Improves Vision in Rare and Devastating Retinal Disordermsn.com - May 7 at 8:47 PMEditas Medicine Q1 2024 Earnings Previewmsn.com - May 7 at 3:47 PMWhat Wall Street expects from Editas Medicine's earningsmarkets.businessinsider.com - May 7 at 10:46 AMCRISPR gene editing shows promise for treating individuals with a form of inherited blindnessmsn.com - May 6 at 7:41 PMClinical trial shows measurable improvement in inherited blindness after gene therapymsn.com - May 6 at 7:41 PMEditas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%finance.yahoo.com - May 5 at 9:37 AMEditas Medicine (EDIT) to Release Earnings on Wednesdaymarketbeat.com - May 3 at 10:32 AMEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Eventsglobenewswire.com - May 2 at 7:00 AMStocks search for direction ahead of Fed rate decisionuk.finance.yahoo.com - May 2 at 12:05 AMEditas, Bristol Myers extend T cell therapy collaborationmsn.com - May 1 at 2:04 PMEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaborationglobenewswire.com - May 1 at 8:00 AMEditas Medicine, Inc. (NASDAQ:EDIT) Sees Large Increase in Short Interestmarketbeat.com - April 29 at 10:39 PMZacks Research Analysts Boost Earnings Estimates for Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 26 at 10:37 AMEditas to present gene editing advancements at ASGCTinvesting.com - April 24 at 8:00 PMEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meetingglobenewswire.com - April 22 at 4:31 PMMirae Asset Global Investments Co. Ltd. Sells 177,556 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 20 at 4:54 AMEditas Medicine Inc (EDIT)investing.com - April 18 at 12:22 PMEditas Medicine (NASDAQ:EDIT) Hits New 52-Week Low at $6.05marketbeat.com - April 15 at 3:58 PMEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest Updatemarketbeat.com - April 14 at 2:55 PMInternational Assets Investment Management LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 10 at 5:08 AMDr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officerfinance.yahoo.com - April 9 at 8:23 AMVanguard Group Inc. Has $66.58 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 8 at 4:08 AMEditas Medicine, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.85) Per Share (NASDAQ:EDIT)marketbeat.com - March 22 at 7:49 AMEditas Medicine, Inc. Forecasted to Earn FY2026 Earnings of ($2.80) Per Share (NASDAQ:EDIT)marketbeat.com - March 21 at 8:36 AMShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 7.4%marketbeat.com - March 18 at 7:26 PMEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)seekingalpha.com - March 13 at 7:58 PMEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)seekingalpha.com - March 12 at 3:56 PM1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.fool.com - March 7 at 3:31 AMEditas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)seekingalpha.com - March 6 at 5:05 PM1 Beaten-Down Stock With 55% Upside, According to Wall Streetfool.com - March 4 at 10:30 AMTrexquant Investment LP Purchases 107,776 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - March 4 at 6:37 AMWhy Editas Medicine Stock Soared as Much as 42% Higher This Weekfool.com - March 2 at 9:49 PMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - March 2 at 2:14 AMStrong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimismmarkets.businessinsider.com - March 1 at 10:17 AMHold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potentialmarkets.businessinsider.com - February 29 at 1:51 PMEditas Medicine (NASDAQ:EDIT) Price Target Raised to $16.00 at Citigroupmarketbeat.com - February 29 at 12:44 PMQ4 2023 Editas Medicine Inc Earnings Callfinance.yahoo.com - February 29 at 1:24 AMEditas Medicine files for mixed shelf offeringmsn.com - February 28 at 8:23 PMEditas Medicine Shares Rally After Reni-cel Study Upgrademarketwatch.com - February 28 at 3:23 PM Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. EDIT Media Mentions By Week EDIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼-0.130.36▲Average Medical News Sentiment EDIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼183▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Voyager Therapeutics News Today C4 Therapeutics News Today Lexeo Therapeutics News Today Fate Therapeutics News Today Tourmaline Bio News Today Taysha Gene Therapies News Today Humacyte News Today Replimune Group News Today iTeos Therapeutics News Today Allogene Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
